Clinical and Hematological Predictors of Response to First-Line Therapy in Patients With Diffuse Large B-Cell Lymphoma

Klinicheskaya Onkogematologiya/Clinical Oncohematology - Russian Federation
doi 10.21320/2500-2139-2019-12-1-68-72
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Practical Medicine Publishing House

Related search

First-Line Therapy of CD20+ Diffuse Large B-Cell Lymphoma: Facts and Open Questions

Haematologica
Hematology
2009English

Clinical Significance of T-Cell Exhaustion in Patients With Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Efficacy and Tolerability of Anthracycline-Based Therapy in Elderly Patients With Diffuse Large B-Cell Lymphoma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2015English

Diffuse Large B-Cell Lymphoma

2020English

Population Pharmacokinetics of Rituximab in Patients With Diffuse Large B-Cell Lymphoma and Association With Clinical Outcome

British Journal of Clinical Pharmacology
Pharmacology
2017English

Noninvasive Phosphorus Magnetic Resonance Spectroscopic Imaging Predicts Outcome to First-Line Chemotherapy in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma

Academic Radiology
Nuclear MedicineRadiologyImaging
2013English

Antiviral Therapy and Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma (Dlbcl) With Hepatitis C (Hcv)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

High-Risk Patients With Diffuse Large B-Cell Lymphoma Are Not Enrolled on Clinical Trials

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma

Seminars in Hematology
Hematology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy